[Form 4] Beyond Meat, Inc. Insider Trading Activity

Rhea-AI Filing Summary

MEI Pharma, Inc. (MEIP) – Form 144 filing

A holder has notified intent to sell up to 611,440 common shares through TD Securities (USA) LLC, targeting 23 Jul 2025. The proposed block carries an aggregate market value of US$3.79 million, implying a price near US$6.20 per share. The shares equal roughly 2.0 % of MEI Pharma’s 29.88 million shares outstanding.

The seller purchased the shares for cash in an open-market transaction on 15 Mar 2023 and reports no other sales in the past three months. By signing, the filer affirms possession of no undisclosed adverse information.

Positive

• None.

Negative

• Additional share supply: Proposed sale of 611,440 shares (~2 % of outstanding) could exert near-term price pressure once executed.

Insights

Securities Analyst

TL;DR: 611k-share Form 144 (~2% float) is a modest supply overhang and mildly negative.

The filing signals a potential insider or large shareholder exit of US$3.8 million worth of stock. While 2 % of outstanding shares is not outsized, it can pressure a small-cap name like MEIP if executed quickly, particularly given limited liquidity. Absence of other recent sales and the fact that shares were bought on the open market in 2023 temper concerns, but investors often view Form 144 activity as a short-term bearish indicator.

Portfolio Manager

TL;DR: Sale intention is minor relative to float; impact depends on trading volume.

At ~US$3.8 million, the block equals one to two days of average volume for many micro-caps, so market impact may be transient if the broker stages the sale. Lack of disclosed relationship makes motive unclear. Still, monitoring execution and any additional filings is prudent before adjusting position sizing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

LUO YI

(Last) (First) (Middle)

C/O BEYOND MEAT, INC.

888 N. DOUGLAS STREET, STE 100

(Street)

EL SEGUNDO CA 90245

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BEYOND MEAT, INC. [ BYND ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
07/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/22/2025		F		552(1)	D	$4.22	21,852	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld to pay taxes applicable to vesting of restricted stock units previously awarded pursuant to the 2018 Equity Incentive Plan.

Remarks:

Title: Vice President, Corporate Controller, Principal Accounting Officer

	/s/ Teri L. Witteman, as Attorney-In-Fact for Yi Luo	07/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many MEIP shares are being sold under this Form 144?

The notice covers 611,440 common shares.

What is the aggregate market value of the proposed MEIP sale?

The filer lists an aggregate value of US$3.79 million.

When is the approximate sale date for the MEIP shares?

The filer indicates an approximate sale date of 23 July 2025.

What percentage of MEI Pharma’s outstanding shares does the block represent?

The 611,440 shares equal roughly 2 % of the 29.88 million shares outstanding.

Where will the MEIP shares be sold?

The shares are slated for sale on the NASDAQ via TD Securities (USA) LLC.